research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Infliximab-Associated Psoriasiform Alopecia
Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
research Baricitinib-Induced Trichilemmal Cyst Reactivation in a Woman With Alopecia Areata
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
research Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
RC48 shows promise for treating certain advanced cancers, but more research is needed.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study
The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
research 1495 Dimethyl fumarate ameliorates delayed wound healing due to IL-36Ra deficiency through inhibition of NET formation and oxidative stress
Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.
research One of the best treatments for alopecia areata remains unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
JAK inhibitors show promise in treating difficult skin diseases.
research P368 Rare skin disorders in IBD patients treated with anti-TNFs
Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
research Managing Azathioprine-Induced Myelosuppression and Alopecia Totalis: Lessons from a SLE Patient
Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.
research 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
research Antibody-drug conjugate induced hair loss responds to minoxidil: A case report
Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
research PRIDE syndrome associated with panitumumab treatment – case report and literature review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.